Cullinan Oncology, Inc. Upon mutual agreement between Patrick Baeuerle and Cullinan Oncology, Inc. (the “Company”), Dr. Baeuerle will transition from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor of the Company effective June 8, 2023. Dr. Baeuerle will also serve as chair of the Company's scientific advisory board. On June 8, 2023, the Company entered into a consulting agreement with Dr. Baeuerle to reflect this mutual understanding.

The consulting agreement has an initial term ending on December 31, 2024, subject to automatic renewal on an annual basis unless earlier terminated pursuant to the agreement.